

JPET #97303

Title Page

M₂ and M₃ Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction.

I. Normal Rat Bladder

Alan S. Braverman, Amit S. Tibb and Michael R. Ruggieri, Sr.

From the Departments of Urology (ASB, AST and MRR) and Pharmacology (MRR), Temple
University School of Medicine, Philadelphia , PA

Running Page

Running title: Normal Bladder M₂ and M₃ Contractile Signal Transduction

Corresponding Author:

Michael R. Ruggieri, Sr.

715 OMS

3400 N Broad St.

Philadelphia, PA 19140

215-707-4567

215-707-4565 (fax)

email:rugg1@msn.com

text pages: 30; # tables: 4; #figures: 2; # references: 40; # words Abstract: 249.

words Introduction: 450; # words Discussion: 1495.

Recommended section assignment: Gastrointestinal, Hepatic, Pulmonary and Renal.

Abbreviations: cAMP, cyclic adenosine monophosphate; CPI-17, Protein kinase C-potentiated phosphatase inhibitor of 17 kDa; CRC, concentration response curve; DAG, diacylglycerol; IP₃, inositol 3,4,5-triphosphate; MYPT-1, regulatory myosin phosphatase targeting sub-unit 1; MLC, myosin light chain; PC-PLC, phosphatidyl choline specific phospholipase C; PKC, protein kinase C; PKG, protein kinase G; PIP₃, phosphatidylinositol 3,4,5-trisphosphate; PI-PLC, phosphoinositide specific phospholipase C; PKA, protein kinase A; PKG, protein kinase G; PLA₂, Phospholipase A₂; PLD, Phospholipase D; RGS, regulator of G-protein signaling, ROCK, rho kinase; SR, sarcoplasmic reticulum.

ABSTRACT:

The muscarinic receptor subtype activated signal transduction mechanisms mediating rat urinary bladder contraction are incompletely understood. M_3 mediate normal rat bladder contractions, however, the M_2 receptor subtype has a more dominant role in contractions of the hypertrophied bladder. Normal bladder muscle strips were exposed to inhibitors of enzymes thought to be involved in signal transduction in-vitro followed by a single cumulative concentration response curve to the muscarinic receptor agonist carbachol. The outcome measures were the maximal contraction, the potency of carbachol, and the affinity of the M_3 selective antimuscarinic agent darifenacin for inhibition of contraction. Inhibition of PI-PLC with ET-18-OCH₃ reduces carbachol potency and reduces darifenacin affinity, while inhibition of PC-PLC with D609 attenuates the carbachol maximal contraction. Inhibition of rho kinase with Y-27632 reduces carbachol potency and increases darifenacin affinity. Inhibition of rho kinase, PKA and PKG with HA-1077 reduces the carbachol maximal contraction, carbachol potency and darifenacin affinity. Inhibition of PKC with chelerythrine increases darifenacin affinity while inhibition of rho kinase, PKA, PKG, and PKC with H7 reduces the carbachol maximum, carbachol potency while increasing darifenacin affinity. Inhibition of rho kinase, PKA and PKG with H89 reduces carbachol maximum and carbachol potency. Both the M_2 and the M_3 receptor subtype are involved in normal rat bladder contractions. The M_3 subtype appears to mediate contraction by activation of PI-PLC, PC-PLC, and PKA, while the M_2 signal transduction cascade may include activation of rho kinase, PKC, and an additional contractile signal transduction mechanism independent of rho kinase or PKC.

INTRODUCTION

Pharmacologic data, based on the actions of subtype-selective antimuscarinic agents, can distinguish four subtypes of muscarinic acetylcholine receptors ($M_1 - M_4$). Molecular techniques have identified five muscarinic receptor subtypes (M_1-M_5) arising from five separate genes (Caulfield, 1993). Both M_2 and M_3 muscarinic receptor subtypes are found in most smooth muscles. The M_2 receptor preferentially couples to the inhibition of adenylyl cyclase through the G_i family of proteins, while the M_3 receptor preferentially couples to IP_3 generation and calcium mobilization through the G_q family of proteins (Caulfield, 1993). Pertussis toxin (PTX), which ADP ribosylates and therefore inactivates the G_i family of proteins, has no apparent effect on contraction (Sawyer and Ehlert, 1999). Even though the M_2 muscarinic receptor density is greater than the M_3 receptor density in bladder and other smooth muscles, the affinity of subtype selective muscarinic receptor antagonist drugs indicates that contraction is mediated by the M_3 receptor in most smooth muscles under normal conditions (Caulfield, 1993; Sawyer and Ehlert, 1999). While not directly involved in mediating smooth muscle contraction, we and others have shown that prejunctional M_1 receptors mediate augmentation of neuronal acetylcholine release and M_2 receptors inhibit acetylcholine release (Somogyi and de Groat, 1992; Braverman et al., 1998a).

Subsequent steps in the contractile signal transduction pathway are not known for certain in bladder smooth muscle but one possibility involves $G_{q/11}$ activation of phosphatidylinositol specific phospholipase C (PI-PLC) which generates IP_3 and diacylglycerol (DAG). IP_3 is thought to act on sarcoplasmic reticulum (SR) IP_3 receptors inducing release of internal stores of

JPET #97303

calcium which sequentially activates calmodulin and myosin light chain kinase. Recent studies indicate that this pathway is not involved in mediating contraction because complete suppression of IP₃ production with the PI-PLC inhibitor U 73122 has no effect on cholinergic contractions of the rat (Schneider et al., 2004b) or human (Schneider et al., 2004a) bladder.

Results from many studies in gastrointestinal (Murthy and Makhlof, 1997; Murthy et al., 2003a; Zhou et al.), airway (Yang et al., 1996; Sohn et al., 2000) vascular (Horowitz et al., 1996; Woodrum et al., 1999; Rembold et al., 2000; Komalavilas et al., 2001), bladder and uterine smooth muscle (Taggart et al., 1999) and cells transfected with muscarinic receptor subtypes (May et al., 1999; Strassheim et al., 1999; Wang et al., 1999; Rumenapp et al., 2001; Ruiz-Velasco et al., 2002; Murthy et al., 2003b) indicate that many signal transduction enzymes are involved in muscarinic receptor mediated contraction and are summarized in figure 1. Few if any of these previously published studies were designed to determine which muscarinic receptor subtype mediates which of these pathways or the interaction between the pathways activated by the individual receptor subtypes.

METHODS:

Materials: The following drugs or chemicals were obtained from the sources indicated. Sigma Chemical Company, St. Louis, Mo: carbachol. Biomol, Plymouth Meeting, PA: ET-18-OCH₃ (1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine), D609 (O-Tricyclo[5.2.1.0^{2,6}]dec-9-yl dithiocarbonate potassium salt), Y-27632 ((R)-(+)-trans-4-(1-Aminoethyl)-N-(4-Pyridyl)cyclohexanecarboxamide dihydrochloride), HA-1077 (1-(5-Isoquinolinesulfonyl)-homopiperazine-HCl), chelerythrine (1,2-Dimethoxy-N-methyl(1,3)benzodioxolo(5,6-c)phenanthridinium chloride), H7 ((1-(5-Isoquinolinesulfonyl)-2-methylpiperazine·2HCl) and H89 (N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide·2HCl). Darifenacin was a generous gift from Pfizer Limited (Sandwich, Kent).

Muscle Strips: Urinary bladders were removed from rats euthanized by CO₂ asphyxiation. The urinary bladder body (tissue above the ureteral orifices) was dissected free of the serosa and surrounding fat. The bladder was divided in the mid-sagittal plane, and cut into longitudinal smooth muscle strips (approximately 3 mm x 8 mm). The muscle strips were then suspended with 1 g of tension in tissue baths containing 15 ml of modified Tyrode's solution (125 mM NaCl, 2.7 mM KCl, 0.4 mM NaH₂PO₄, 1.8 mM CaCl₂, 0.5 mM MgCl₂, 23.8 mM NaHCO₃, and 5.6 mM glucose) and equilibrated with 95/5% O₂/CO₂ at 37 °C.

Carbachol Concentration Response: Following equilibration to the bath solution for 30 minutes, a maximal contraction induced by a 3 minute exposure to 120 mM potassium was recorded. The strips were ranked based on their contractile response to KCl and sorted so that

JPET #97303

the average response in each treatment group was equal. The strips were incubated for 30 minutes in the presence or absence of an enzyme inhibitor and in the presence or absence of 30 nM darifenacin. Because higher doses of darifenacin appeared insurmountable and lower doses did not produce a significant shift in the concentration response curve, a single dose of 30 nM darifenacin was used. Dose response curves were derived from the peak tension developed following cumulative addition of carbachol (10 nM to 300 μ M final bath concentration) and normalized to the response to 120 mM KCl. Only one concentration of enzyme inhibitor and or darifenacin was used for each muscle strip.

The target enzymes and K_i for the enzyme inhibitors are listed in table 1. The 3 different enzyme inhibitor concentrations used were based on these concentrations reported for isolated, purified enzymes starting at just above the published K_i and increasing at half log intervals. Dose ratios were determined based on the average responses of antagonist free strips. Because some of the enzyme inhibitors decreased the maximal contraction to less than 50 %, darifenacin affinity is based on EC_{25} values. The EC_{25} and EC_{50} values were determined for each strip using a sigmoidal curve fit of the data (Origin, Originlab Corp. Northampton, MA.). The EC_{25} values determined in the presence of darifenacin were used to estimate the pK_b and the dose ratios were determined using the same concentration of inhibitor with and without darifenacin. The estimated pK_b for darifenacin was calculated using the formula $pK_b = -(\log[\text{darifenacin concentration}] - \log(\text{dose ratio} - 1))$.

Because there were statistically significant differences in the variance between groups, statistical analysis of multiple group comparisons was performed by non-parametric Kruskal-

JPET #97303

Wallis analysis of variance followed by a post hoc Mann-Whitney U test for pair wise comparisons (GB-STAT, Dynamic Microsystems, Silver Spring, MD). Because there was no statistical difference between the outcome measures for the different vehicle control groups, these data were pooled. For maximal contraction and carbachol potency, groups with enzyme inhibitors were compared to these pooled, no inhibitor added, vehicle controls.

RESULTS:

Inhibition of Phospholipases: Inhibition of PI-PLC with ET-18-OCH₃ has no effect on the carbachol stimulated maximal contraction response. A representative graph of the data for ET-18-OCH₃ is shown in figure 2 and table 3 includes this and data for all of the enzyme inhibitors used. Inhibition of PI-PLC with both 30 μ M and 100 μ M ET-18-OCH₃ decreases carbachol potency. Furthermore, when the strips were exposed to the highest concentration of ET-18-OCH₃ (100 μ M), the affinity of darifenacin for inhibiting contraction was significantly lower than in strips exposed to vehicle only. Inhibition of PC-PLC with 100 μ M D609 reduces the maximal contraction with no effect on carbachol potency or darifenacin affinity. Lower concentrations of D609 have no significant effects. The non-specific PLC inhibitor neomycin has only minor effects: a statistically significant reduction in the maximal contraction at the lowest concentration used with no effect at higher concentrations.

Inhibition of protein kinases: Inhibition of ROCK with 3 μ M and 10 μ M Y-27632 reduces carbachol potency with no effect on the maximal contraction. Additionally, darifenacin affinity is significantly increased following ROCK inhibition with both 1 μ M and 10 μ M Y-27632. Inhibition of ROCK along with PKG and PKA by all concentrations of HA-1077 decreases the carbachol maximal contraction and carbachol potency and at the same time decreases darifenacin affinity. Inhibition of PKC with chelerythrine has no effect on the maximal contraction response or carbachol potency. Inhibition of PKC does significantly increase darifenacin affinity. Inhibition of ROCK, PKA, PKC and PKG by all concentrations of H7 reduces the maximal carbachol contraction and carbachol potency. The 2 highest concentrations

JPET #97303

of H7 (3 and 10 μ M) increase darifenacin affinity. Inhibition of PKA, ROCK, and PKG with both 3 μ M and 10 μ M H89 reduces the maximal carbachol contraction while all concentrations used reduce carbachol potency. H89 has no effect on darifenacin affinity.

DISCUSSION:

Our earlier studies demonstrated that the M_2 receptor subtype participates in mediating contraction from several experimental pathological conditions which result in hypertrophy (Braverman et al., 1998b; Braverman et al., 2000; Braverman et al., 2002; Braverman and Ruggieri, 2003). Because the M_2 subtype preferentially couples to G_{α_i} , while the M_3 subtype preferentially couples to G_{α_q} , this led to the hypothesis that the signal transduction pathways activated by the two receptor subtypes are different and may act in parallel to mediate contraction. Darifenacin is an M_3 selective muscarinic antagonist with about a 30 fold selectivity for M_3 over M_2 receptors. The affinity of darifenacin for inhibiting carbachol stimulated contraction is high in normal bladders consistent with the M_3 receptor subtype mediating contraction (Braverman and Ruggieri, 2003). A change in affinity of darifenacin to lower values induced by a given enzyme inhibitor suggests involvement of that enzyme in a signal transduction pathway mediated by the M_3 receptor. On the other hand, if an enzyme inhibitor increases the affinity of darifenacin, this may suggest the involvement of the inhibited enzyme in a parallel signal transduction pathway mediated by the M_2 receptor. Decreasing the maximal agonist induced contraction or the agonist potency with no change in darifenacin affinity could suggest the involvement of that enzyme in both M_2 and M_3 mediated pathways. A summary of our findings implicating the different possible signal transduction enzymes in M_2 and M_3 mediated contractile pathways is shown in table 4.

The PI-PLC inhibitor ET-18-OCH₃ reduces carbachol potency and darifenacin affinity indicating the possible involvement of PI-PLC in mediating the M_3 contractile signal. This

JPET #97303

suggests that the M_2 receptor subtype has a greater role in mediating contraction following PI-PLC inhibition. Because D609 inhibits maximal contraction with no effect on darifenacin affinity, this suggests that PC-PLC is activated by both M_2 and M_3 receptors. Since the contraction following PC-PLC inhibition is mediated by the M_3 receptor subtype, this suggests that PC-PLC is essential for maximal force generation. Similar findings have been reported in the cat lower esophageal sphincter (Biancani et al., 1994). In permeabilized, isolated cat detrusor smooth muscle cells, inhibition of contraction with antibodies to G-proteins and PI-PLC isoforms indicates that cholinergic contraction occurs by M_3 activation of $G_{\alpha q/11}$, PI-PLC-1 and IP_3 -dependent calcium release (An et al., 2002). Studies using M_2 and M_3 knockout mice indicate that M_2 receptors mediate bladder contraction indirectly by inhibition of adenylyl cyclase (Ehlert et al., 2005), however, findings in isolated rabbit intestine circular smooth muscle cells indicate that M_2 receptors can activate contraction directly through $G\beta\gamma_{13}$ -dependent activation of PI-PLC- β_3 (Murthy et al., 2003a).

Our data differs from other reports of PI-PLC mediating rat and human bladder contraction (Fleischman et al., 2004; Schneider et al., 2004a; Schneider et al., 2004b). These reports concluded that bladder contraction via M_3 receptors largely depends on calcium entry through nifedipine-sensitive channels and activation of ROCK whereas phospholipase D and store-operated calcium channels contribute in a minor way and phospholipase C or PKC do not seem to be involved. This is likely due to differences in experimental paradigms. In our paradigm, each muscle strip is exposed to one single agonist concentration response curve (CRC) in separate smooth muscle strips with and without the enzyme inhibitor. The previously published

studies performed 5 repetitive CRCs in the same smooth muscle strip with increasing concentrations of enzyme inhibitor. We found that following 5 successive carbachol CRCs, the affinity of the M₃ selective antagonist para-fluoro hexahydro siladifenadol was shifted to a lower value, consistent with M₂ receptors participating in the contraction (data not shown). Others have shown that the M₃ receptor subtype is subject to agonist induced desensitization (Tobin et al., 1992; Willets et al., 2001; Willets et al., 2002; Griffin et al., 2004). Therefore M₃ receptor desensitization may occur during the repeated agonist CRCs which could explain these differences.

Recently much attention has been focused on calcium sensitization induced by the small GTP binding protein rho (Taggart et al., 1999; Murthy et al., 2003a; Fleichman et al., 2004; Schneider et al., 2004a). Calcium sensitization refers to the ability of the muscle to generate the same contractile force with lower levels of intracellular calcium and is likely due to inhibition of MLC phosphatase. Smooth muscle contractile force is largely a function of the phosphorylation state of myosin light chain. This phosphorylation state is in a balance between the activity of myosin light chain kinase and myosin light chain phosphatase. Rho kinase has been shown to phosphorylate CPI-17 which dramatically increases the inhibitory activity of CPI-17 on MLC phosphatase activity (Koyama et al., 2000). Y-27632, a specific inhibitor of rho kinase (Uehata et al., 1997), reduces carbachol potency and increases darifenacin affinity. This suggests that the M₃ receptor subtype mediates contraction following inhibition of the rho pathway and that the rho pathway is activated by M₂ receptor activation. The finding that inhibition of the rho pathway in normal bladders results in decreased carbachol potency with no decrease in the

carbachol maximal contraction, suggests that this pathway is active in normal bladders, but maximal contraction is not critically dependent on inhibition of MLC phosphatase.

HA-1077 has about a 5 fold higher affinity for inhibition of ROCK than PKA and PKG (Nagumo et al., 2000). When PKA and PKG along with ROCK are inhibited by HA-1077 there is a decrease in carbachol potency, a decrease in the carbachol maximum and a decrease in darifenacin affinity. The reduction in carbachol potency is likely the result of ROCK inhibition, because the specific ROCK inhibitor Y-27632 reduces carbachol potency. However, ROCK inhibition alone has no effect on the carbachol maximum, thus inactivation of either PKA or PKG blocks the carbachol maximum. The darifenacin affinity is decreased following inhibition of PKA, PKG and ROCK by HA-1077, but is increased following inhibition of only ROCK with Y-27632. This suggests that when ROCK is inhibited, PKA or PKG becomes involved in the pathway activated by the M₃ receptor and mediates contraction with only a decrease in carbachol potency. Once all 3 of these enzymes are inhibited, contraction occurs via an M₂ mediated pathway independent of ROCK, PKA and PKG.

Inhibition of PKC by chelerythrine has no effect on the carbachol maximum or carbachol potency. However, the darifenacin affinity is increased following PKC inhibition which suggests that PKC is involved in the M₂ receptor contractile signal transduction pathway. There are at least 11 different isoforms of PKC (α , β I, β II, γ , δ , ϵ , η , θ , μ , ζ and λ) and the isoform mediating this M₂ contractile pathway in rat bladder is not known. Because PKC α has been reported to be relatively insensitive to inhibition by chelerythrine (Lee et al., 1998; Davies et al.,

2000), it is likely that isoforms other than PKC α mediate this M₂ receptor activated contractile signal transduction pathway in rat bladder.

H89 has about a 5 fold higher affinity for inhibiting PKA than ROCK and about a 10 fold higher affinity for inhibiting PKA than PKG (Leemhuis et al., 2002). H89 inhibits the carbachol maximum and carbachol potency with no effect on darifenacin affinity. Because inhibition of ROCK alone only results in a decrease in carbachol potency, the decrease in carbachol maximum is likely the result of inhibition of PKA following H89. This suggests that PKA may be involved in mediating the M₃ contractile signal.

H7 has a about a 6 fold higher affinity for inhibition of ROCK than PKA and about a 10 fold higher affinity for inhibiting ROCK than PKC and PKG (Uehata et al., 1997). H7 inhibits the maximum contraction and carbachol potency while increasing darifenacin affinity suggesting that following inhibition of these enzymes, the M₃ receptor mediates contraction, but the remaining contractile signal is insufficient to stimulate maximum force. These results, as well as the results with HA-1077 suggest that PKA is involved in mediating the M₃ contractile signal. Because the darifenacin affinity is increased following H7, the M₃ receptor predominately mediates contraction in the presence of H7. However, when ROCK, PKA and PKG are inhibited with HA-1077, the residual contraction is mediated by the M₂ receptor. This difference is likely because HA-1077 does not inhibit PKC while H7 does. This result, as does the chelerythrine result described above, suggests that PKC is involved in mediating the M₂ contractile pathway.

JPET #97303

Our results suggest that in normal bladders, where the M₃ receptor subtype predominantly mediates contraction, PI-PLC, PC-PLC, ROCK, PKC, PKA and/or PKG are all involved in transducing the contractile signal. The M₂ receptor may activate ROCK in the normal rat bladder because darifenacin affinity is increased following ROCK inhibition. This demonstrates that although the M₃ receptor appears to predominate in mediating contraction, the M₂ receptor does participate in the contractile signal. The contractile pathways activated by muscarinic receptors in the rat urinary bladder are complex, with redundant signaling pathways which become active when other signaling systems are inhibited. This redundant mechanism includes a more dominant role for the M₂ receptor following M₃ receptor desensitization, which likely occurs following multiple exposures to agonist.

JPET #97303

ACKNOWLEDGEMENTS:

The authors would like to acknowledge the expert technical assistance provided by Neil Lamarre, Kimberly Buck and Bernadette Simpkins.

REFERENCES:

- An JY, Yun HS, Lee YP, Yang SJ, Shim JO, Jeong JH, Shin CY, Kim JH, Kim DS and Sohn UD (2002) The intracellular pathway of the acetylcholine-induced contraction in cat detrusor muscle cells. *British Journal of Pharmacology* **137**:1001-1010.
- Biancani P, Harnett KM, Sohn UD, Rhim BY, Behar J, Hillemeier C and Bitar KN (1994) Differential signal transduction pathways in cat lower esophageal sphincter tone and response to ACh. *American Journal of Physiology*. **266**:G767-774.
- Braverman AS, Bartula LL, Myers SI, Parkman HP and Ruggieri MR (2000) Inflammation Changes the Muscarinic Receptor Subtype and Signal Transduction Pathway That Mediates Gallbladder Contraction. *Gastroenterology* **118**:A197.
- Braverman AS, Kohn IJ, Luthin GR and Ruggieri MR (1998a) Prejunctional M1 facilitory and M2 inhibitory muscarinic receptors mediate rat bladder contractility. *American Journal of Physiology*. **274**:R517-523.
- Braverman AS, Luthin GR and Ruggieri MR (1998b) M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. *American Journal of Physiology*. **275**:R1654-1660.
- Braverman AS and Ruggieri MR, Sr. (2003) Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. *American Journal of Physiology - Regulatory Integrative & Comparative Physiology* **285**:R701-708.
- Braverman AS, Tallarida RJ and Ruggieri MR, Sr. (2002) Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. *American*

Journal of Physiology - Regulatory Integrative & Comparative Physiology. **283**:R663-668.

Caulfield MP (1993) Muscarinic receptors--characterization, coupling and function.

Pharmacology & Therapeutics **58**:319-379.

Davies SP, Reddy H, Caivano M and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochemical Journal* **351**:95-105.

Ehlert FJ, Griffin MT, Abe DM, Vo TH, Taketo MM, Manabe T and Matsui M (2005) The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. *Journal of Pharmacology & Experimental Therapeutics* **313**:368-378.

Fleischman M, Schneider T, Fetscher C and Michel MC (2004) Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. *Journal of Pharmacology & Experimental Therapeutics*. **308**:54-58.

Griffin MT, Matsui M, Shehnaz D, Ansari KZ, Taketo MM, Manabe T and Ehlert FJ (2004) Muscarinic agonist-mediated heterologous desensitization in isolated ileum requires activation of both muscarinic M2 and M3 receptors. *Journal of Pharmacology & Experimental Therapeutics*. **308**:339-349.

Horowitz A, Clement-Chomienne O, Walsh MP and Morgan KG (1996) Epsilon-isoenzyme of protein kinase C induces a Ca(2+)-independent contraction in vascular smooth muscle. *American Journal of Physiology* **271**:C589-594.

Komalavilas P, Mehta S, Wingard CJ, Dransfield DT, Bhalla J, Woodrum JE, Molinaro JR and Brophy CM (2001) PI3-kinase/Akt modulates vascular smooth muscle tone via cAMP

signaling pathways. *Journal of Applied Physiology* **91**:1819-1827.

Koyama M, Ito M, Feng J, Seko T, Shiraki K, Takase K, Hartshorne DJ and Nakano T (2000)

Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. *FEBS Letters* **475**:197-200.

Lee SK, Qing WG, Mar W, Luyengi L, Mehta RG, Kawanishi K, Fong HH, Beecher CW,

Kinghorn AD and Pezzuto JM (1998) Angoline and chelerythrine, benzophenanthridine alkaloids that do not inhibit protein kinase C. *Journal of Biological Chemistry* **273**:19829-19833.

Leemhuis J, Boutillier S, Schmidt G and Meyer DK (2002) The protein kinase A inhibitor H89

acts on cell morphology by inhibiting Rho kinase. *Journal of Pharmacology & Experimental Therapeutics* **300**:1000-1007.

May LG, Johnson S, Krebs S, Newman A and Aronstam RS (1999) Involvement of protein

kinase C and protein kinase A in the muscarinic receptor signalling pathways mediating phospholipase C activation, arachidonic acid release and calcium mobilisation. *Cellular Signalling*. **11**:179-187.

Murthy KS and Makhlof GM (1997) Differential coupling of muscarinic m2 and m3 receptors

to adenylyl cyclases V/VI in smooth muscle. Concurrent M2-mediated inhibition via Galphai3 and m3-mediated stimulation via Gbetagammaq. *Journal of Biological Chemistry*. **272**:21317-21324.

Murthy KS, Zhou H, Grider JR, Brautigan DL, Eto M and Makhlof GM (2003a) Differential

signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of

JPET #97303

myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway. *Biochemical Journal* **374**:145-155.

Murthy KS, Zhou H, Grider JR and Makhlof GM (2003b) Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. *American Journal of Physiology - Gastrointestinal & Liver Physiology*. **284**:G1006-1016.

Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M and Takuwa Y (2000) Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. *American Journal of Physiology - Cell Physiology* **278**:C57-65.

Rembold CM, Foster DB, Strauss JD, Wingard CJ and Eyk JE (2000) cGMP-mediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation in swine carotid artery. *Journal of Physiology*. **524**:865-878.

Ruiz-Velasco R, Lanning CC and Williams CL (2002) The activation of Rac1 by M3 muscarinic acetylcholine receptors involves the translocation of Rac1 and IQGAP1 to cell junctions and changes in the composition of protein complexes containing Rac1, IQGAP1, and actin. *Journal of Biological Chemistry*. **277**:33081-33091.

Rumenapp U, Asmus M, Schablowski H, Woznicki M, Han L, Jakobs KH, Fahimi-Vahid M, Michalek C, Wieland T and Schmidt M (2001) The M3 muscarinic acetylcholine

JPET #97303

- receptor expressed in HEK-293 cells signals to phospholipase D via G12 but not Gq-type G proteins: regulators of G proteins as tools to dissect pertussis toxin-resistant G proteins in receptor-effector coupling. *Journal of Biological Chemistry*. **276**:2474-2479.
- Sawyer GW and Ehlert FJ (1999) Muscarinic M3 receptor inactivation reveals a pertussis toxin-sensitive contractile response in the guinea pig colon: evidence for M2/M3 receptor interactions. *Journal of Pharmacology & Experimental Therapeutics*. **289**:464-476.
- Schneider T, Fetscher C, Krege S and Michel MC (2004a) Signal transduction underlying carbachol-induced contraction of human urinary bladder. *Journal of Pharmacology & Experimental Therapeutics* **309**:1148-1153.
- Schneider T, Hein P and Michel MC (2004b) Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca²⁺ sources. *Journal of Pharmacology & Experimental Therapeutics*:47-53.
- Sohn UD, Hong YW, Choi HC, Ha JH, Lee KY, Kim WJ, Biancani P, Jeong JH and Huh IH (2000) Increase of [Ca²⁺]_i and release of arachidonic acid via activation of M2 receptor coupled to Gi and rho proteins in oesophageal muscle. *Cellular Signalling*. **12**:215-222.
- Somogyi GT and de Groat WC (1992) Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. *Journal of the Autonomic Nervous System*. **37**:89-97.
- Strassheim D, May LG, Varker KA, Puhl HL, Phelps SH, Porter RA, Aronstam RS, Noti JD and Williams CL (1999) M3 muscarinic acetylcholine receptors regulate cytoplasmic myosin

JPET #97303

by a process involving RhoA and requiring conventional protein kinase C isoforms.

Journal of Biological Chemistry. **274**:18675-18685.

Taggart MJ, Lee YH and Morgan KG (1999) Cellular redistribution of PKC α , rhoA, and ROK α following smooth muscle agonist stimulation. *Experimental Cell Research.* **251**:92-101.

Tobin AB, Lambert DG and Nahorski SR (1992) Rapid desensitization of muscarinic m3 receptor-stimulated polyphosphoinositide responses. *Molecular Pharmacology.* **42**:1042-1048.

Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M and Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.[see comment]. *Nature* **389**:990-994.

Wang YX, Dhulipala PD, Li L, Benovic JL and Kotlikoff MI (1999) Coupling of M2 muscarinic receptors to membrane ion channels via phosphoinositide 3-kinase gamma and atypical protein kinase C. *Journal of Biological Chemistry.* **274**:13859-13864.

Willems JM, Challiss RA, Kelly E and Nahorski SR (2001) G protein-coupled receptor kinases 3 and 6 use different pathways to desensitize the endogenous M3 muscarinic acetylcholine receptor in human SH-SY5Y cells. *Molecular Pharmacology.* **60**:321-330.

Willems JM, Challiss RA and Nahorski SR (2002) Endogenous G protein-coupled receptor kinase 6 Regulates M3 muscarinic acetylcholine receptor phosphorylation and desensitization in human SH-SY5Y neuroblastoma cells. *Journal of Biological*

Chemistry. **277**:15523-15529.

Woodrum DA, Brophy CM, Wingard CJ, Beall A and Rasmussen H (1999) Phosphorylation events associated with cyclic nucleotide-dependent inhibition of smooth muscle contraction. *American Journal of Physiology*. **277**:H931-939.

Yang CM, Hsu MC, Tsao HL, Chiu CT, Ong R, Hsieh JT and Fan LW (1996) Effect of cAMP elevating agents on carbachol-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. *Cell Calcium*. **19**:243-254.

Zhou H, Das S and Murthy KS (2003) Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA2 by m3 and m2 receptors. *American Journal of Physiology*. **284**:G472-480.

JPET #97303

Footnotes:

Supported by PHS grant RO1 DK43333 to MRR.

FIGURE LEGENDS:

Figure 1. Diagram of potential muscarinic receptor stimulated signal transduction mechanisms.

Figure 2. A. Cumulative carbachol concentration response curves of rat bladder contraction with and without the PI-PLC inhibitor ET-18-OCH₃. The maximal carbachol response in the absence of any inhibitor is 121±5 % of the response to 120 mM KCl (2.41±0.14 g) and the carbachol EC₅₀ is 1.9±0.6 μM. B. Effect of ET-18-OCH₃ on the maximal carbachol response. C. Effect of ET-18-OCH₃ on carbachol EC₅₀. No inhibitor (n= 41); 10 μM (n=18); 30 μM (n=4); 100 μM (n=4). For figures 2-9 * denotes p<0.05, ** denotes p<0.01 compared to no inhibitor.

JPET #97303

Table 1. K_i for inhibitors at various lipases (μM) .

Inhibitor	PI-PLC	PC-PLC
ET-18-OCH ₃	5	
D609		94
Neomycin	5	5

JPET #97303

Table 2. K_i for inhibitors at various kinases (μM).

Inhibitor	PKA	PKG	PK C	ROCK
Y-27632	25		26	0.1
HA-1077	1.6	1.6		0.33
Chelerytherine			0.66	
H7	3	5.8	6	0.45
H89	0.05	0.5		0.27

Table 3. Effect of enzyme inhibitors on normal rat urinary bladder contractions.

Enzyme Inhibitor	Target Enzymes	Concentration (μM)	Carbachol Maximam (% KCl)	Carbachol EC_{50} (μM)	Darifenacin Affinity (nM)
Vehicle			117.8 \pm 4.7	2.4 \pm 0.2	5.3 \pm 1.0
ET-18-OCH ₃	PI-PLC	10	116.8 \pm 3.6	4.5 \pm 1.8	8.7 \pm 3.3
		30	110.5 \pm 4.8	12.7 \pm 3.2**	3.7 \pm 1.0
		100	102.4 \pm 2.8	32.7 \pm 16.9**	15.4 \pm 4.9*
D609	PC-PLC	10	113.8 \pm 6.3	2.8 \pm 0.8	4.2 \pm 0.9
		30	91.4 \pm 5.9	3.4 \pm 0.2	3.8 \pm 1.1
		100	50.1 \pm 9.5**	10.8 \pm 5.9	2.1 \pm 1.1
Neomycin	PLC	10	90.3 \pm 5.3**	1.3 \pm 0.1	3.1 \pm 1.2
		30	115.2 \pm 9.1	2.1 \pm 0.6	5.3 \pm 1.9
		100	124.7 \pm 15.2	1.6 \pm 0.5	1.1 \pm 0.5
Y-27632	ROCK	1	101.4 \pm 7.1	3.0 \pm 0.7	0.2 \pm 0.03**
		3	106.7 \pm 11.4	6.7 \pm 1.8**	0.7 \pm 0.3
		10	110.1 \pm 9.8	12.7 \pm 3.4**	0.3 \pm 0.1*
HA-1077	ROCK, PKA, PKG	10	73.2 \pm 5.3**	22.0 \pm 6.3**	9.8 \pm 3.2
		30	70.5 \pm 6.2**	16.4 \pm 9.7**	6.4 \pm 4.8
		100	47.2 \pm 10.4**	25.8 \pm 10.3**	20.4 \pm 3.8**
Chelerytherine	PKC	1	101.8 \pm 9.8	5.4 \pm 3.3	2.6 \pm 0.6
		3	114.8 \pm 11.4	2.0 \pm 0.5	0.3 \pm 0.04**
		10	128.5 \pm 17.7	2.4 \pm 0.2	0.3 \pm 0.1**
H7	ROCK, PKA, PKG, PKC	10	75.2 \pm 5.3**	17.3 \pm 5.4	10.7 \pm 4.9
		30	82.0 \pm 6.6**	8.0 \pm 2.1	0.3 \pm 0.1**
		100	57.6 \pm 9.7**	19.6 \pm 6.8	0.5 \pm 0.2**
H89	PKA, ROCK, PKG	1	142.5 \pm 12.1	5.6 \pm 1.4**	6.6 \pm 5.2
		3	100.4 \pm 11.3*	3.8 \pm 0.8*	3.1 \pm 1.4
		10	53.0 \pm 6.8**	13.5 \pm 4.6**	6.2 \pm 3.2

Table 4. Summary of findings.

Enzyme	M ₂ pathways	M ₃ pathways
PI-PLC	ET-18-OCH ₃ decreases carbachol potency	ET-18-OCH ₃ decreases darifenacin affinity ET-18-OCH ₃ decreases carbachol potency
PC-PLC	D609 decreases carbachol potency	D609 decreases carbachol potency
ROCK	Y-27632 decreases darifenacin affinity Y-27632 decreases carbachol potency HA1077 decreases carbachol maximum HA1077 decreases carbachol potency H7 increased darifenacin affinity H7 decreases carbachol maximum H89 decreases carbachol maximum H89 decreases carbachol potency	HA1077 decreases darifenacin affinity HA1077 decreases carbachol maximum HA1077 decreases carbachol potency H89 decreases carbachol maximum H89 decreases carbachol potency
PKA	H7 increases darifenacin affinity H89 decreases carbachol maximum H89 decreases carbachol potency	H89 decreases carbachol maximum H89 decreases carbachol potency
PKC	Chelerytherine increases darifenacin affinity H7 increases darifenacin affinity	
PKG	H89 decreases carbachol maximum H89 decreases carbachol potency	H89 decreases carbachol maximum H89 decreases carbachol potency

Figure 2

